Core Insights - Watts Water (WTS) reported quarterly earnings of $2.5 per share, exceeding the Zacks Consensus Estimate of $2.29 per share, and up from $2.03 per share a year ago, representing an earnings surprise of +9.17% [1] - The company achieved revenues of $611.7 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.90%, and an increase from $543.6 million year-over-year [2] - Watts Water's stock has increased by approximately 35.1% year-to-date, outperforming the S&P 500's gain of 15.1% [3] Earnings Outlook - The future performance of Watts Water's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is $2.06 on revenues of $561.06 million, and for the current fiscal year, it is $9.86 on revenues of $2.34 billion [7] Industry Context - The Instruments - Control industry, to which Watts Water belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Traeger reported a quarterly loss of $0.17 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.03, marking an earnings surprise of -466.67% [1] - The company achieved revenues of $125.4 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 11.39% and showing a year-over-year increase from $122.05 million [2] - Traeger shares have declined approximately 62.1% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Financial Performance - Over the last four quarters, Traeger has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is $0.03, with projected revenues of $146.68 million, and for the current fiscal year, the estimate remains at $0.03 with revenues of $548.08 million [7] Market Outlook - The estimate revisions trend for Traeger was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The Consumer Products - Discretionary industry, to which Traeger belongs, is currently ranked in the bottom 30% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Insights - LiveRamp (RAMP) reported quarterly earnings of $0.55 per share, exceeding the Zacks Consensus Estimate of $0.48 per share, and showing an increase from $0.51 per share a year ago, resulting in an earnings surprise of +14.58% [1] - The company achieved revenues of $199.83 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.83% and up from $185.48 million year-over-year [2] - LiveRamp has outperformed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times in the same period [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.71 on revenues of $209.97 million, and for the current fiscal year, it is $2.21 on revenues of $807.67 million [7] - The estimate revisions trend for LiveRamp was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Technology Services industry, to which LiveRamp belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Phibro Animal Health (PAHC) reported quarterly earnings of $0.73 per share, exceeding the Zacks Consensus Estimate of $0.59 per share, and showing significant growth from $0.35 per share a year ago [1][2] - The company achieved revenues of $363.9 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.60% and increasing from $260.4 million year-over-year [3] - Phibro's stock has appreciated approximately 100.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.1% [4] Earnings Performance - The earnings surprise for the recent quarter was +23.73%, following a previous surprise of +9.62% when actual earnings were $0.57 compared to an expected $0.52 [2] - Over the last four quarters, Phibro has consistently surpassed consensus EPS estimates [2] Future Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [4] - Current consensus EPS estimate for the upcoming quarter is $0.62 on revenues of $357.21 million, and for the current fiscal year, it is $2.59 on revenues of $1.46 billion [8] - The estimate revisions trend for Phibro was favorable ahead of the earnings release, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [7]

Core Insights - Nutrien (NTR) reported quarterly earnings of $0.97 per share, exceeding the Zacks Consensus Estimate of $0.93 per share, and significantly up from $0.39 per share a year ago, representing an earnings surprise of +4.30% [1] - The company achieved revenues of $6.01 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.09% and up from $5.35 billion year-over-year [2] - Nutrien's stock has increased approximately 19.9% since the beginning of the year, outperforming the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.83 on revenues of $5.47 billion, while for the current fiscal year, the estimate is $4.56 on revenues of $26.76 billion [7] - The estimate revisions trend for Nutrien was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Fertilizers industry, to which Nutrien belongs, is currently ranked in the bottom 24% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Procore Technologies reported quarterly earnings of $0.42 per share, exceeding the Zacks Consensus Estimate of $0.31 per share, and showing an increase from $0.24 per share a year ago, resulting in an earnings surprise of +35.48% [1] - The company achieved revenues of $338.85 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.49% and increasing from $295.89 million year-over-year [2] - Procore Technologies has outperformed consensus EPS estimates three times over the last four quarters and has topped revenue estimates four times in the same period [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.37 on revenues of $338.72 million, while the estimate for the current fiscal year is $1.26 on revenues of $1.3 billion [7] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Internet - Software industry, to which Procore Technologies belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Franklin Covey reported quarterly earnings of $0.34 per share, missing the Zacks Consensus Estimate of $0.43 per share, and down from $0.89 per share a year ago, indicating an earnings surprise of -20.93% [1] - The company posted revenues of $71.25 million for the quarter ended August 2025, surpassing the Zacks Consensus Estimate by 0.39%, but down from $84.12 million year-over-year [2] - Franklin Covey shares have declined approximately 55.2% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Earnings Outlook - The future performance of Franklin Covey's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $64.8 million, and for the current fiscal year, it is $0.80 on revenues of $267.62 million [7] Industry Context - The Consulting Services industry, to which Franklin Covey belongs, is currently ranked in the top 14% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Franklin Covey's stock performance [5][6]

Core Insights - Energy Recovery (ERII) reported quarterly earnings of $0.12 per share, exceeding the Zacks Consensus Estimate of $0.09 per share, but down from $0.21 per share a year ago, indicating an earnings surprise of +33.33% [1] - The company achieved revenues of $32 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 7.51%, although this is a decrease from year-ago revenues of $38.58 million [2] - Energy Recovery shares have increased approximately 11.6% year-to-date, compared to a 15.1% gain in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.70 on revenues of $84.83 million, and for the current fiscal year, it is $0.71 on revenues of $149.9 million [7] - The estimate revisions trend for Energy Recovery was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Pollution Control industry, to which Energy Recovery belongs, is currently ranked in the bottom 26% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Another company in the same industry, Donaldson (DCI), is expected to report quarterly earnings of $0.92 per share, reflecting a year-over-year change of +10.8% [9]

分组1 - CF Industries reported quarterly earnings of $2.19 per share, exceeding the Zacks Consensus Estimate of $2.06 per share, and up from $1.55 per share a year ago, representing an earnings surprise of +6.31% [1] - The company posted revenues of $1.66 billion for the quarter ended September 2025, which was below the Zacks Consensus Estimate by 0.34%, but an increase from $1.37 billion year-over-year [2] - CF has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed the market, losing about 0.9% since the beginning of the year compared to the S&P 500's gain of 15.1% [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimate for the coming quarter at $2.12 on revenues of $1.71 billion, and $8.73 on revenues of $6.98 billion for the current fiscal year [7] - The Zacks Industry Rank indicates that the Fertilizers sector is currently in the bottom 24% of over 250 Zacks industries, which may impact stock performance [8]

Core Insights - Catalyst Pharmaceutical (CPRX) reported quarterly earnings of $0.68 per share, exceeding the Zacks Consensus Estimate of $0.51 per share, and showing an increase from $0.57 per share a year ago, resulting in an earnings surprise of +33.33% [1][2] - The company achieved revenues of $148.39 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 8.77% and up from $128.7 million year-over-year [2] - Catalyst has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The future performance of Catalyst's stock will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.48 on revenues of $137.08 million, and for the current fiscal year, it is $2.29 on revenues of $561.49 million [7] Industry Context - The Medical - Drugs industry, to which Catalyst belongs, is currently ranked in the top 40% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of Catalyst's stock may also be influenced by the overall industry outlook and trends [8] Competitor Insights - Guardian Pharmacy Services (GRDN), another company in the same industry, is expected to report quarterly earnings of $0.24 per share, reflecting a year-over-year increase of +112%, with revenues projected at $353.95 million, up 12.6% from the previous year [9][10]